Results 171 to 180 of about 420,890 (308)

Delineating gender/sex‐related studies through bibliometric analysis

Journal of the Association for Information Science and Technology, EarlyView.
Abstract The multidisciplinary and socially grounded nature of Women's/Gender/Feminist Studies poses unique challenges for bibliometric analysis, as it extends beyond conventional disciplinary boundaries. This paper makes three key contributions: (1) We propose a novel retrieval method for constructing a corpus of scholarly documents in research areas ...
Natsumi S. Shokida, Diego Kozlowski, Vincent Larivière   +2 more
wiley   +1 more source

Review of \u3cem\u3eAesthetic Revolutions and Twentieth-Century Avant-Garde Movements\u3c/em\u3e Edited by Aleš Erjavec [PDF]

, 2016
Carter, Curtis
core   +1 more source

Trends in 25 years of antihypertensive agent utilization in Croatia – an alert for scientific community and healthcare providers

British Journal of Clinical Pharmacology, EarlyView.
Aims Hypertension is a leading modifiable risk factor for cardiovascular mortality worldwide. This study aimed to evaluate 25‐year trends in antihypertensive agent (AHA) utilization in Croatia between 2000 and 2024. Methods We conducted a national, population‐based analysis using IMS and IQVIA pharmaceutical databases.
Andrej Belančić, Marta Kučan Štiglić, Ana Jelaković, Bojan Jelaković, Dinko Vitezić   +4 more
wiley   +1 more source

Politics and Scientific Publishing: Noli Me Tangere

Molecular Therapy, 2002
openaire   +2 more sources

Beyond the label: Rethinking off‐label drug use in paediatrics. Towards a scientifically grounded and safer future for paediatric pharmacotherapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Despite regulatory progress being made in the past two decades, off‐label drug use in paediatrics remains pervasive, with prevalence estimated between 3% and 97% of prescriptions across different clinical settings. Off‐label use—defined as prescribing outside the conditions described in the Summary of Product Characteristics (SmPC)—is often ...
Tjitske M. van der Zanden, Miriam G. Mooij, Matthijs de Hoog, Saskia N. de Wildt   +3 more
wiley   +1 more source

Editorial: Decoding and bridging the tripartite components of One Health: collaborative strategies for global well-being. [PDF]

Front Public Health
Stefanis C, Tsigalou C, Stavropoulou E.
europepmc   +1 more source

Zuranolone: A case study in (regulatory) rush to judgement?

British Journal of Clinical Pharmacology, EarlyView.
Abstract Sage, in collaboration with Biogen, submitted a new drug approval for zuranolone for postpartum depression (PPD) and major depressive disorder (MDD) in December 2022. In August 2023, the US Food and Drug Administration granted approval for PPD but denied approval for MDD.
Lisa Cosgrove, Milutin Kostic, Barbara Mintzes, Gianna D'Ambrozio, Allen Shaughnessy   +4 more
wiley   +1 more source

Editorial: Gender, civil society and women's movements in the context of Russia's war on Ukraine. [PDF]

Front Sociol
Hinterhuber EM, Fuchs G.
europepmc   +1 more source

Advanced therapy medicinal products (ATMPs) – An analysis of the global regulatory status

British Journal of Clinical Pharmacology, EarlyView.
Abstract Background A rapid progress in the development of advanced therapy medicinal products (ATMPs) has taken place over the past decades. The ATMPs hold great potential but face challenges in the clinical development and the regulatory process.
Allan Cramer, Freja Karuna Hemmingsen Sørup, Marie Lund, Tonny Studsgaard Petersen, Kristian Karstoft   +4 more
wiley   +1 more source

From pilot to policy: why AI health interventions fail to scale in developing countries. [PDF]

Front Digit Health
Joseph J.
europepmc   +1 more source